Gemtuzumab Ozogamicin

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1037 publications

Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia.

Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia.

Journal: Expert opinion on pharmacotherapy

Published: October 13, 2026

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: July 31, 2026

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.

Journal: Journal of managed care & specialty pharmacy

Published: July 27, 2026

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2026

Outcomes with fractionated gemtuzumab ozogamicin in molecularly defined favorable-risk acute myeloid leukemia.

Outcomes with fractionated gemtuzumab ozogamicin in molecularly defined favorable-risk acute myeloid leukemia.

Journal: Blood cancer journal

Published: June 23, 2026

Molecular Heterogeneity of Core Binding Factor Acute Myeloid Leukemia (CBF-AML): Implications for Prognosis and for Treatment.

Molecular Heterogeneity of Core Binding Factor Acute Myeloid Leukemia (CBF-AML): Implications for Prognosis and for Treatment.

Journal: Hematology reports

Published: June 18, 2026

Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-transplant Relapsed AML.

Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-transplant Relapsed AML.

Journal: Transplantation and cellular therapy

Published: June 09, 2026

Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-Transplant Relapsed AML.

Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-Transplant Relapsed AML.

Journal: Transplantation and cellular therapy

Published: June 09, 2026

Orbital Myeloid Sarcoma Masquerading as Orbital Cellulitis: A Diagnostic Challenge in an Adult Patient.

Orbital Myeloid Sarcoma Masquerading as Orbital Cellulitis: A Diagnostic Challenge in an Adult Patient.

Journal: Cureus

Published: June 02, 2026

Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.

Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.

Journal: Journal of clinical medicine

Published: May 23, 2026

Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).

Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).

Journal: Frontiers in immunology

Published: May 23, 2026

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Journal: Blood advances

Published: May 13, 2026

Showing 1-12 of 1,037

Last Updated: 11/08/2026